Yue Linkai, Xiao Lu, Zhang Xuemin, Niu Liqing, Wen Yue, Li Xiaowei, Wang Ying, Xing Guanghe, Li Guiwei
Department of Emergency, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Front Pharmacol. 2024 Feb 27;15:1348360. doi: 10.3389/fphar.2024.1348360. eCollection 2024.
Cardiogenic shock (CS) is the primary cause of death in patients suffering acute myocardial infarction. As an emerging and efficacious therapeutic approach, Chinese herbal injections (CHIs) are gaining significant popularity in China. However, the optimal CHIs for treating CS remain uncertain. We searched eight databases from inception to 30 September 2023. Subsequently, we conducted the Bayesian network meta-analysis (NMA). Interventions were ranked based on the surface under the cumulative ranking curve (SUCRA) probability values. To compare the effects of CHIs on two distinct outcomes, a clustering analysis was performed. Furthermore, the quality of the studies was assessed. For the study, we included 43 RCTs, encompassing 2,707 participants. The study evaluated six herbal injections, namely, Shenfu injection (SF), Shengmai injection (SM), Shenmai injection (Sm), Danshen injection (DS), Huangqi injection (HQ), and Xinmailong injection (XML). The analysis findings suggested that Sm (MD = -1.05, 95% CI: -2.10, -0.09) and SF (MD = -0.81, 95% CI: -1.40, -0.25) showed better efficacy compared to Western medicine (WM) alone in reducing in-hospital mortality. The SUCRA values revealed that Sm + WM ranked first in terms of in-hospital mortality, cardiac index (CI), and hourly urine output but second in improving left ventricular ejection fraction (LVEF) and mean arterial pressure (MAP). SF + WM, however, had the greatest impact on raising the clinical effective rate. In MAP, SM + WM came out on top. Moreover, in terms of safety, only 14 studies (31.8%), including five types of CHIs: SF, Sm, SM, HQ, and XML, observed adverse drug reactions. To summarize, this analysis discovered that, in terms of patients suffering from CS, CHIs + WM yielded significantly greater advantages than WM alone. Based on in-hospital mortality and the remaining outcomes, Sm performed excellently among all the involved CHIs. : https:// www.Crd.york.ac.uk/prospero/, identifier: CRD42022347053.
心源性休克(CS)是急性心肌梗死患者死亡的主要原因。作为一种新兴且有效的治疗方法,中药注射剂(CHIs)在中国越来越受欢迎。然而,治疗CS的最佳中药注射剂仍不确定。我们检索了从数据库建立到2023年9月30日的八个数据库。随后,我们进行了贝叶斯网络荟萃分析(NMA)。干预措施根据累积排序曲线下面积(SUCRA)概率值进行排名。为了比较中药注射剂对两个不同结局的影响,进行了聚类分析。此外,还评估了研究的质量。在本研究中,我们纳入了43项随机对照试验,涉及2707名参与者。该研究评估了六种中药注射剂,即参附注射液(SF)、生脉注射液(SM)、参麦注射液(Sm)、丹参注射液(DS)、黄芪注射液(HQ)和心脉隆注射液(XML)。分析结果表明,与单纯西药(WM)相比,Sm(MD = -1.05,95%CI:-2.10,-0.09)和SF(MD = -0.81,95%CI:-1.40,-0.25)在降低住院死亡率方面显示出更好的疗效。SUCRA值显示,Sm + WM在住院死亡率、心脏指数(CI)和每小时尿量方面排名第一,但在改善左心室射血分数(LVEF)和平均动脉压(MAP)方面排名第二。然而,SF + WM对提高临床有效率的影响最大。在MAP方面,SM + WM排名第一。此外,在安全性方面,只有14项研究(31.8%)观察到药物不良反应,这些研究涉及五种中药注射剂:SF、Sm、SM、HQ和XML。总之,该分析发现,对于CS患者,中药注射剂 + 西药比单纯西药具有显著更大的优势。基于住院死亡率和其他结局,Sm在所有涉及的中药注射剂中表现出色。: https:// www.Crd.york.ac.uk/prospero/, 标识符: CRD42022347053